Using a new ventilation method for patients with severe lung injury
Official title: Early Use of Airway Pressure Release Ventilation (APRV) in Patients With Acute Respiratory Distress Syndrome
Run by Hospital Civil de Guadalajara · NCT04221737 · Data updated 2026-11-12
This study is testing a new breathing method for patients with severe lung injury to see if it helps them breathe better and need less medication compared to standard treatments.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Hospital Civil de Guadalajara Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Guadalajara, Jalisco) |
| Status | Recruiting |
| Started | July 15, 2017 |
| Main results expected | November 2026 |
| Study ends | December 2026 |
| Registry record updated | September 17, 2026 |
| Trial ID | NCT04221737 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults diagnosed with ARDS who have been on mechanical ventilation for less than 48 hours.
✕Probably not a fit
Patients with preexisting conditions that predict a high mortality risk or those requiring very short-term mechanical ventilation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the early use of Airway Pressure Release Ventilation (APRV) compared to conventional mechanical ventilation in patients suffering from Acute Respiratory Distress Syndrome (ARDS). The study aims to determine the effects and safety of APRV, which allows for spontaneous breathing and improved gas exchange, in a multi-center, randomized, controlled setting. By focusing on patients who have been on mechanical ventilation for less than 48 hours, the trial seeks to assess whether this innovative approach can enhance oxygenation and reduce the need for sedation and neuromuscular blockers. The ultimate goal is to improve patient outcomes and reduce mortality associated with ARDS.
Why it matters
Potential benefit: If successful, this approach could significantly improve oxygenation and reduce mortality rates in patients with ARDS.
How similar studies have gone: While APRV is considered a non-conventional ventilatory mode, its effectiveness compared to standard methods in ARDS patients is still being explored, indicating a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Acute respiratory distress syndrome, according to the Berlin definition of ARDS, with adjusted pO2/FiO2 for altitude \<300, and less than 48 h of endotracheal mechanical ventilation Exclusion Criteria: * Pregnancy * Less than 18 years-old * Expected duration of mechanical ventilation less than 48 h * Preexisting conditions with an expected 3-month mortality exceeding 50% * Concurrent chemotherapy * Confirmed intracranial hypertension * Catastrophic cranial trauma or neuromuscular disorders that are known to prolong mechanical ventilation * Pneumothorax at enrollment (resolved or not) * Do-not-resuscitate order
Where it's running
-
Hospital Civil Fray Antonio Alcalde
Guadalajara, Jalisco, Mexico Recruiting
Study contacts
- Principal investigator: Miguel Ibarra-Estrada, Dr — Hospital Civil Fray Antonio Alcalde
- Study coordinator: Miguel Ibarra-Estrada, Dr
- Email: drmiguelibarra@hotmail.com
- Phone: 3317593502
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Full-Course ECMO Pathway for Moderate-to-Severe ARDS
This study tests a standardized, full-course ECMO management pathway to see if it improves care for adults with moderate-to-severe ARDS treated with VV-ECMO in real-world Chinese centers.
-
Height measurement methods to guide ventilator settings in ARDS
We’re testing whether more precise height measurements change how researchers set lung-protective tidal volumes in adults with ARDS who are on a ventilator.
-
Corticosteroids for a hyperinflammatory state in critical illness
This trial tests whether methylprednisolone helps improve organ function and survival in adults with sepsis or ARDS who show a hyperinflammatory profile.
-
Right‑heart function and heart–lung interaction during ARDS with mechanical ventilation
This project will follow adults with ARDS on mechanical ventilation to see how positive‑pressure breathing affects the right heart over time and how that relates to circulation.
-
Umbilical‑cord mesenchymal stem cell and secretome therapy for severe ARDS
This trial tests whether IV umbilical‑cord mesenchymal stem cells, alone or with secretome, help adults with severe ARDS recover lung function and reduce inflammation.
-
Human umbilical cord mesenchymal stem cell injection for moderate to severe ARDS
This will test whether a single injection of human umbilical cord mesenchymal stem cells can help adults with moderate to severe ARDS that hasn't improved after standard treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.